Cystic Fibrosis

Cystic fibrosis is a life threatening, inherited disease of the exocrine glands. The condition primarily affects the digestive and respiratory systems which become clogged with a thick, sticky mucus. Cystic fibrosis is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in an excess of salt and water passing into cells, causing a thick, sticky mucus to build up in bodily passageways.

Cystic Fibrosis (CF)

Cystic fibrosis is a genetic condition that affects the production and flow of mucus within the lungs and digestive system, parts of the body that then become clogged with a thick, sticky mucus.

Cystic Fibrosis Causes

Cystic Fibrosis Symptoms

Cystic Fibrosis Diagnosis

Cystic Fibrosis Treatment

Genetics of Cystic Fibrosis

Cystic Fibrosis Screening

Cystic Fibrosis Questions

Coping With Cystic Fibrosis

Cystic Fibrosis Facts

Cystic Fibrosis Epidemiology

Cystic Fibrosis Prognosis

See more featured articles »

Cystic Fibrosis Research

Could CRISPR Repair CFTR in Cystic Fibrosis Patients?

Sweat Test for Cystic Fibrosis

Cystic Fibrosis and Salty Skin

Cystic Fibrosis Evolution

Lung Transplantation for Cystic Fibrosis

Gene Therapy as a Potential Cure for Cystic Fibrosis

Cystic Fibrosis and Infertility

Cystic Fibrosis History

Tests for Cystic Fibrosis During Pregnancy

Latest Cystic Fibrosis News and Research

Researchers to investigate real-world effects of new cystic fibrosis medications

Researchers at RCSI University of Medicine and Health Sciences are leading a new €3m study to investigate the real-world effects of the newest cystic fibrosis medications as they become available for people with CF.

30 Jul 2020

Researchers launch randomized, placebo-controlled clinical trial of pulmozyme in COVID-19 patients

Researchers at Boston Children's Hospital and Brigham and Women's Hospital have launched a randomized, placebo-controlled clinical trial of dornase alfa (Pulmozyme) in patients with severe COVID-19 pneumonia and respiratory failure requiring mechanical ventilation.

29 Jul 2020

Arcturus and Duke-NUS announce approval of clinical trials for COVID-19 vaccine candidate

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, and Duke-NUS Medical School, Singapore's flagship research-intensive graduate entry medical school, today announced that the Clinical Trial Application for COVID-19 vaccine candidate LUNAR-COV19 has been approved to proceed by the Singapore Health Sciences Authority.

22 Jul 2020

More than half of American children lack cardiorespiratory fitness

A new study strengthens the claim that children today are not as healthy as those decades ago. In fact, the study by researchers on behalf of the American Heart Association (AHA) has found that nearly 60 percent of American children do not have healthy cardiorespiratory fitness (CRF), a key measure of physical fitness and overall health.

20 Jul 2020

World's first technology aims to help diagnose, treat and manage people with cystic fibrosis

World-first research led by Monash University could hold the key to better monitoring and treatment of lung disease associated with cystic fibrosis (CF) – a condition thousands of people are diagnosed with each year.

15 Jul 2020

Human lungs rejected for transplant can be recovered using cross-circulation with pigs

A new experiment by researchers at the Columbia Engineering and Vanderbilt University may have the solution to this long-standing problem. The team revived and repaired the damaged lungs by cross-circulation support of the whole lungs outside the body using the circulatory system with that of a living pig.

14 Jul 2020

Vav3 protein promotes cystic fibrosis, shows study

Cystic fibrosis, one of the most common genetic diseases in Switzerland, causes severe respiratory and digestive disorders.

14 Jul 2020

Repurposed drug for acute lung injury in COVID-19

Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.

2 Jul 2020

Chemist develops new drug to treat type 2 diabetes without undesired side effects

Syracuse University chemistry professor Dr. Robert P. Doyle has developed a new drug lead to treat type 2 diabetes in millions of patients who are seeking to better control their blood sugar without the common side effects of nausea, vomiting, and in select cases, undesired weight loss.

23 Jun 2020

Study identifies new gene variants tied to type-2 diabetes

After examining the genes of more than 200,000 people all over the world who have type-2 diabetes, researchers from the Perelman School of Medicine at the University of Pennsylvania and the Veterans Health Administration's Corporal Michael J. Crescenz Veterans Affairs Medical Center found hundreds of genetic variants never before linked to the disease.

23 Jun 2020

Researchers develop a simple tool for making mouse models of COVID-19

Until there are effective treatments or vaccines, the COVID-19 pandemic will remain a significant threat to public health and economies around the world. A major hurdle to developing and testing new anti-viral therapies and vaccines for COVID-19 is the lack of good, widely available animal models of the disease.

16 Jun 2020

Novel disease may lead to a better understanding of cystic fibrosis

Cystic fibrosis is the most frequent severe inherited disorder worldwide. Every year, hundreds of families are confronted with this diagnosis - and to date, there is no cure for this disease that mainly affects the respiratory system.

5 Jun 2020

Genome-based monitoring of multi-resistant pathogen can help improve infection control

S. maltophilia strains occur in several natural and human associated ecosystems. The bacterium was long regarded as relatively unproblematic but is now considered to be one of the most feared hospital pathogens, as it frequently causes infections and is resistant to a number of antibiotics.

15 May 2020

ACMG: Technical standard on CFTR variant testing updated

It has been nearly two decades since the American College of Medical Genetics and Genomics, together with the American College of Obstetricians and Gynecologists, made the landmark recommendation that cystic fibrosis (CF) become the first target of pan-ethnic universal carrier screening, with ACMG identifying a core panel of 23 pathogenic variants to be tested.

14 May 2020

New antibiotic fights drug-resistant bacteria without notable toxic side-effects

Through serendipity, researchers at the University of Pittsburgh Graduate School of Public Health considerably reduced the toxicity of a potential antibiotic against the most feared drug-resistant bacteria, while also improving its stability in fighting infections.

4 May 2020

Long-lasting, low toxicity antimicrobial peptide fights 'superbug' lung infections

Researchers considerably reduced the toxicity of a potential antibiotic against the most feared drug-resistant bacteria.

1 May 2020

New insights into self-management plans for children with chronic conditions

With stressed hospital services, and concerns about the spread of COVID-19, experts are reminding carers of children and young people of the importance of adhering to supported chronic condition self-management plans from the safety of their home.

22 Apr 2020

Are overactive immune cells causing COVID-19-related deaths?

While the COVID-19 pandemic is devastating many regions, the world over, a new paper published in the Journal of Experimental Medicine in April 2020 describes the possibility that the critical or very severe cases of COVID-19 are due to the production of neutrophil extracellular traps (NET) due to hyperactivated immune cells.

16 Apr 2020

Tuberculosis bacteria facilitate their spread by producing a molecule that triggers cough

The bacteria that cause the deadly lung disease tuberculosis appear to facilitate their own spread by producing a molecule that triggers cough, a new study led by UTSW researchers shows.

5 Mar 2020

Treatments for rare diseases affecting children are increasing, study suggests

The number of treatments for rare diseases affecting children has increased, a new study suggests. But federal incentives intended to encourage drug development for rare conditions are being used more often to expand the use of existing drugs rather than for creating new ones.

3 Mar 2020